DAX23.458 -0,9%ESt505.428 -0,7%Top 10 Crypto15,33 -1,9%Dow45.951 -0,4%Nas22.233 -1,2%Bitcoin94.973 -1,6%Euro1,1684 -0,5%Öl68,53 -0,8%Gold3.731 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 Gerresheimer A0LD6E Alibaba A117ME Tesla A1CX3T SAP 716460 HENSOLDT HAG000 Siemens Energy ENER6Y DroneShield A2DMAA Plug Power A1JA81 Novo Nordisk A3EU6F Volkswagen (VW) vz. 766403 Commerzbank CBK100 D-Wave Quantum A3DSV9
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX gibt nach -- Wall Street tiefer -- EU-Kommission ermittelt gegen SAP -- Intel wirbt um Apple als Investor -- D-Wave, Droneshield, BYD, Plug Power, Novo Nordisk im Fokus
Top News
Oracle-Aktie im Visier: Milliarden am Anleihemarkt für KI-Infrastruktur eingesammelt Oracle-Aktie im Visier: Milliarden am Anleihemarkt für KI-Infrastruktur eingesammelt
Richtungssuche setzt sich fort: DAX am Donnerstag im Rückwärtsgang Richtungssuche setzt sich fort: DAX am Donnerstag im Rückwärtsgang
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Marketing-Anzeige: Sie legen an, wir legen nach! +++ 1% Bonus bis zu 1.000 € bei Solidvest sichern +++ Nur noch bis 30.09.

REGENXBIO Aktie

Kaufen
Verkaufen
REGENXBIO Aktien-Sparplan
8,05 EUR +0,55 EUR +7,33 %
FSE
9,32 USD -0,24 USD -2,51 %
BTT
REGENXBIO jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.384,01 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA140E0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75901B1070

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRGNX

REGENXBIO Aktien News

DatumMeistgelesen
PR NewswireREGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
PR NewswireREGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
PR NewswireREGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
PR NewswireREGENXBIO Announces Leadership Transition
PR NewswireREGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PR NewswireREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
PR NewswireREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
PR NewswireREGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
PR NewswireREGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
PR NewswireREGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
PR NewswireREGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
PR NewswireREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
PR NewswireREGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireREGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
PR NewswireREGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
PR NewswireREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
PR NewswireREGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
PR NewswireREGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society
PR NewswireREGENXBIO to Participate in Upcoming Investor Conferences
PR NewswireInitial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium
PR NewswireREGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
PR NewswireREGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference
PR NewswireREGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
PR NewswireREGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting
PR NewswireREGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023
PR NewswireREGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates

REGENXBIO News

REGENXBIO News: auf dieser Seite finden Sie alle REGENXBIO News und Nachrichten zur REGENXBIO Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch REGENXBIO News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um REGENXBIO News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.